<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01840566</url>
  </required_header>
  <id_info>
    <org_study_id>12-117</org_study_id>
    <nct_id>NCT01840566</nct_id>
  </id_info>
  <brief_title>High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of delivering the patients' own immune cells,
      called T cells, after the high-dose chemotherapy (HDT) and autologous stem cell
      transplantation (ASCT).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum tolerated dose (MTD)</measure>
    <time_frame>2 years</time_frame>
    <description>will be assessed utilizing a standard 3+3 cell dose escalation to determine the maximum tolerated dose of CD19+ CAR T cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>safety</measure>
    <time_frame>2 years</time_frame>
    <description>Toxicity will be graded on a scale of 1 to 5 as described by the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2 year progression-free (PFS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (os)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>HIGH DOSE CHEMOTHERAPY AND ASCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a phase 1 dose escalation study designed to determine the maximum tolerated dose (MTD) of CAR modified T cells in patients with relapsed and refractory aggressive B-NHL. Three dose levels (5 x 106 19-28z T cells/kg, 1 x 107 19-28z T cells/kg, and 2 x 107 19-28z T cells/kg) are considered for the MTD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carmustine</intervention_name>
    <arm_group_label>HIGH DOSE CHEMOTHERAPY AND ASCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <arm_group_label>HIGH DOSE CHEMOTHERAPY AND ASCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <arm_group_label>HIGH DOSE CHEMOTHERAPY AND ASCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <arm_group_label>HIGH DOSE CHEMOTHERAPY AND ASCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegfilgrastim</intervention_name>
    <arm_group_label>HIGH DOSE CHEMOTHERAPY AND ASCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>19-28z T CELLS</intervention_name>
    <arm_group_label>HIGH DOSE CHEMOTHERAPY AND ASCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Stem Cell Transplantation</intervention_name>
    <arm_group_label>HIGH DOSE CHEMOTHERAPY AND ASCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Transplant eligible patients will be eligible if criteria met per below.

        Inclusion Criteria:

          -  Patients ≥ 18 years of age with aggressive B-cell non-Hodgkin lymphoma subtypes
             including, relapsed or refractory diffused large B-cell lymphoma (DLBCL), and
             transformed follicular lymphoma meeting at least one of the following criteria:

               -  Bone marrow involvement at the time of relapse or refractory disease and not
                  appropriate for allogeneic transplantation.

               -  PET positive disease outside of one radiation port unless single-port disease
                  treated with prior radiotherapy within the port, following &gt; or = to 2 cycles of
                  salvage chemotherapy, still achieving chemosensitive status 1999 IWG criteria
                  (section 12.2 and 12.383).

          -  Creatinine ≤ 1.5 mg/100 ml (or measured 24 hour creatinine clearance of ≥ 50 cc/min)

          -  Bilirubin &lt;2.0 mg/100 ml, AST and ALT &lt;3x the upper-limit of normal, PT and PTT &lt; 2x
             normal outside the setting of stable chronic anticoagulation therapy,

          -  Adequate cardiac function (LVEF&gt;40%) as assessed by ECHO or MUGA scan performed within
             1 month of treatment.

          -  Adequate pulmonary function as assessed by DLCO of &gt; or = to 45% adjusted for
             hemoglobin.

          -  Life expectancy of &gt; 3 months.

        Exclusion Criteria:

          -  Karnofsky performance status ≤ 70 (see appendix VI).

          -  Patients with other aggressive B-cell malignancies including, but not limited to:
             Burkitt lymphoma, transformed CLL/SLL and transformed marginal zone lymphoma that are
             not included in 6.1 inclusion criteria.

          -  Patients previously treated with autologous or allogeneic bone marrow or stem cell
             transplantation are ineligible.

          -  Other past or current malignancy unless in the opinion of the investigator it does not
             contraindicate participation in the study.

          -  Uncontrolled bacterial, viral or fungal infection.

          -  Patients with HIV, active hepatitis B or hepatitis C infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Sauter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2013</study_first_submitted>
  <study_first_submitted_qc>April 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2013</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <keyword>Autologous Stem Cell Transplantation</keyword>
  <keyword>HIGH DOSE CHEMOTHERAPY</keyword>
  <keyword>19-28z T cells/kg</keyword>
  <keyword>12-117</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Carmustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

